Comparative Pharmacology
Head-to-head clinical analysis: THYROLAR 0 25 versus THYROLAR 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THYROLAR 0 25 versus THYROLAR 3.
THYROLAR-0.25 vs THYROLAR-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thyroid hormone (liothyronine, L-triiodothyronine or T3) binds to thyroid hormone receptors in the nucleus, altering gene transcription and protein synthesis, leading to increased metabolic rate, oxygen consumption, and thermogenesis.
THYROLAR-3 is a combination of synthetic T4 (levothyroxine) and T3 (liothyronine) that replaces or supplements endogenous thyroid hormones. T4 is converted to the active T3 in peripheral tissues. Thyroid hormones bind to thyroid hormone receptors (TRα and TRβ), regulating gene transcription involved in metabolism, growth, and development.
Oral, 0.25 mg (1 tablet) once daily; adjust based on TSH response.
Adults: Initial dose 30 mg orally once daily; adjust based on thyroid function tests. Typical maintenance dose 60-120 mg once daily.
None Documented
None Documented
Levothyroxine (T4): ~7 days; liothyronine (T3): ~1 day. Clinical context: Steady-state achieved in ~5 weeks for T4; T3 half-life shorter leads to more frequent dosing if used alone.
Levothyroxine (T4): 6-7 days; Liothyronine (T3): 1-2 days. Clinical context: In hyperthyroidism, half-life shortened; in hypothyroidism, prolonged.
Renal: ~40% as conjugated metabolites (glucuronides and sulfates); fecal: ~20% via bile; minor biliary elimination of parent drug (<5%). Total renal clearance of iodine: ~30%.
Renal (approximately 50% as unchanged drug and conjugates); fecal (~20%); biliary (~10%)
Category C
Category C
Thyroid Hormone
Thyroid Hormone